Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.

Michelle is a lead editor at Forbes Advisor. She has been a journalist for over 35 years, writing about insurance for consumers for the last decade. Prior to covering insurance, Michelle was a ...

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class. The US regulator is reviewing odronextamab ...

On December 9, REGN announced new and positive data for odronextamab monotherapy in patients with previously untreated follicular lymphoma with twelve abstracts spanning several B-cell non-Hodgkin ...

Odronextamab is under clinical development by Regeneron Pharmaceuticals ... The therapeutic candidate is administered intravenously. It is an anti-CD20 and anti-CD3 bi-specific monoclonal antibody. It ...

Functionally bivalent non-covalent Fab dimers (Bi-Fabs) specific for the TCR/CD3 complex promote CD3 signaling on T cells. While comparing functional responses to stimulation with Bi-Fab, F(ab’)2 or ...

The CD3×EpCAM BsAb was isolated through Protein A affinity chromatography (Cytiva, Uppsala, Sweden). The eluates were adjusted to pH 7.0 using Tris-HCl buffer, dialyzed to PBS, and sterilized through ...